Oncopeptides has announced an exclusive distribution and commercialization agreement with Salus for its multiple myeloma drug, Pepaxti, covering 11 countries in Central and Eastern Europe (CEE). This leverages a local partner to unlock a region with an estimated total market potential of SEK150m, driving geographic expansion ahead of the company’s original internal timeline.
LÄS MER
